Fulcrum Therapeutics (FULC) Depreciation & Amortization (CF) (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Depreciation & Amortization (CF) of $338000.0 for Q1 2026, down 4.25% year-over-year from $353000.0 in Q1 2025, and down 15.5% quarter-over-quarter from $400000.0 in Q4 2025.
Fulcrum Therapeutics (FULC) Depreciation & Amortization (CF) (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $338000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $338000.0, down 4.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (down 12.49% YoY), and the FY2025 annual result was $1.4 million, down 12.5% from the prior year.
- Depreciation & Amortization (CF) retreated to $338000.0 in Q1 2026 per FULC's latest filing, from $400000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $700000.0 in Q2 2022 and troughed at $300000.0 in Q2 2025.
- A 5-year average of $467882.4 and a median of $472000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) grew 11.94% in 2023, then plunged 33.33% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $600000.0 in 2022, then retreated by 21.33% to $472000.0 in 2023, then slipped by 20.34% to $376000.0 in 2024, then climbed by 6.38% to $400000.0 in 2025, then declined by 15.5% to $338000.0 in 2026.
- Business Quant data shows FULC's Depreciation & Amortization (CF) at $338000.0 in Q1 2026, $400000.0 in Q4 2025, and $300000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | 338,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 338,000.00 |
| Mar 31, 2026 | 338,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 353,000.00 |
| Mar 31, 2025 | 353,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 479,000.00 |
| Mar 31, 2024 | 479,000.00 |
| Dec 31, 2023 | 472,000.00 |
| Dec 31, 2023 | 472,000.00 |